Next Generation Thrombolysis

Basking is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

Acute Stroke:
Deadly, Disabling, Undertreated

Current Treatment Pathway for Ischemic Stroke

Stroke is the second leading cause of death globally
  • 1.7M annual cases in US, EU5, and Japan
  • Adult global lifetime risk of AIS >18%
Current Treatments reach <15% of all Patients
  • TPA associated bleeding risk limits utilization
  • Clot accessibility and need for a surgeon limit usage of thrombectomy
Stroke is costly with poor outcomes

– Leading cause of long-term disability
~$240B annual US cost in 2030

Our Approach

Acute thrombolytic with reversal agent

DTRI-031 has demonstrated superiority to TPA across multiple murine and canine preclinical models while DTRI-025 provides rapid reversal in the event of bleeding.

Mechanism of Action

Target: von Willebrand Factor
– Non-redundant mediator of platelet adhesion/aggregation
– Prevalent throughout clot structure
– Proven relationship between vWF and risk of stroke/MI

Safety

Reversible and Short Duration
– Neutralization of drug effect in < 5 min if needed
– ~3-hour pharmacodynamic effect
– Well tolerated in GLP toxicology studies

Efficacy

Optimized for Stroke Therapy
– Superior to rTPA in multiple animal models
– Rapid onset of action (< 5 mins.)
– DTRI-025 allows hemostatic modulation

Funding Update

Our recently closed Seed Financing supports development of DTRI-031 through Phase 1B, in parallel with the NIH funded DTRI-025’s IND enabling program.

View Press Release